Refametinib
N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
Molecular Identity
Refametinib
N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
PubChem CID: 44182295
Refametinib is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation.
2D Structure
Properties
C19H20F3IN2O5S
Molecular Formula
572.30
Molecular Weight
g/mol
572.0090
Exact Mass
Da
2.8
XLogP
Drug-like (Lipinski: < 5)
116
TPSA
Good oral absorption (< 140 A²)
4
H-Bond Donors
10
H-Bond Acceptors
711
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
Refametinib923032-37-5RDEA119BAY 869766RDEA-119BAY-869766JPX07AFM0NBAY 8697661BAY-8697661BAY869766N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamideBAY86-9766BAY8697661BAY-86-9766DTXSID40238961
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to Refametinib
Loading drug network...